# Hexarelin Clinical Dosing Guidelines

## Overview
Hexarelin is a synthetic hexapeptide growth hormone-releasing peptide (GHRP) that stimulates growth hormone release through binding to the growth hormone secretagogue receptor (GHSR). It has demonstrated potent GH-releasing activity and cardioprotective effects.

## Clinical Research Summary
Based on clinical trials and research studies, hexarelin has demonstrated efficacy in:
- Growth hormone deficiency treatment
- Cardiovascular protection and cardiac function improvement
- Muscle preservation and growth
- Metabolic dysfunction improvement
- Age-related GH decline reversal
- Body composition enhancement

## Standard Concentrations

### Reconstitution Options
- **Option 1**: 0.1 mg/ml (dilute 2 mg in 20 ml bacteriostatic water)
- **Option 2**: 0.2 mg/ml (dilute 2 mg in 10 ml bacteriostatic water)
- **Option 3**: 0.05 mg/ml (dilute 1 mg in 20 ml bacteriostatic water)

### Storage
- **Lyophilized**: Store at -4°F, stable for 24+ months
- **Reconstituted**: Store at 39°F, use within 28 days
- **Stability**: Maintain proper storage for optimal potency

## Clinical Dosing Protocols

### Subcutaneous Administration (Primary Route)

#### Standard GH Stimulation Protocol:
- **Concentration**: 0.1 mg/ml
- **Dose**: 0.1 mg per injection
- **Volume**: 1.0 ml
- **Frequency**: 3 times daily (morning, midday, night)
- **Duration**: 12-16 weeks with 4-week breaks

#### Cardiovascular Protection Protocol:
- **Concentration**: 0.2 mg/ml
- **Dose**: 0.2 mg per injection
- **Volume**: 1.0 ml
- **Frequency**: Once daily
- **Duration**: Long-term maintenance

#### Body Composition Protocol:
- **Concentration**: 0.1 mg/ml
- **Dose**: 0.1 mg per injection
- **Volume**: 1.0 ml
- **Frequency**: 2-3 times daily
- **Duration**: 16 weeks on, 4 weeks off cycles

### Intravenous Administration (Clinical Setting Only)

#### Acute GH Testing:
- **Concentration**: 0.05 mg/ml
- **Dose**: 0.001-0.002 mg per kg body weight
- **Volume**: Variable based on weight
- **Frequency**: Single dose for testing
- **Monitoring**: GH levels at 15, 30, 60, 90, 120 minutes

## Dose Calculations by Body Weight

### Standard Dosing (0.45 mcg/lb)
| Body Weight | Dose (mg) | Volume (0.1 mg/ml) | Volume (0.2 mg/ml) |
|-------------|-----------|-------------------|-------------------|
| 110 lbs | 0.05 mg | 0.50 ml | 0.25 ml |
| 132 lbs | 0.06 mg | 0.60 ml | 0.30 ml |
| 154 lbs | 0.07 mg | 0.70 ml | 0.35 ml |
| 176 lbs | 0.08 mg | 0.80 ml | 0.40 ml |
| 198 lbs | 0.09 mg | 0.90 ml | 0.45 ml |
| 220 lbs | 0.10 mg | 1.00 ml | 0.50 ml |

### High-Dose Protocol (0.9 mcg/lb - Metabolic Disorders)
| Body Weight | Dose (mg) | Volume (0.1 mg/ml) | Volume (0.2 mg/ml) |
|-------------|-----------|-------------------|-------------------|
| 110 lbs | 0.10 mg | 1.00 ml | 0.50 ml |
| 154 lbs | 0.14 mg | 1.40 ml | 0.70 ml |
| 198 lbs | 0.18 mg | 1.80 ml | 0.90 ml |
| 220 lbs | 0.20 mg | 2.00 ml | 1.00 ml |

### Conservative Dosing (0.23 mcg/lb - Initial Treatment)
| Body Weight | Dose (mg) | Volume (0.05 mg/ml) | Volume (0.1 mg/ml) |
|-------------|-----------|-------------------|-------------------|
| 110 lbs | 0.025 mg | 0.50 ml | 0.25 ml |
| 154 lbs | 0.035 mg | 0.70 ml | 0.35 ml |
| 198 lbs | 0.045 mg | 0.90 ml | 0.45 ml |
| 220 lbs | 0.050 mg | 1.00 ml | 0.50 ml |

## Clinical Applications

### Growth Hormone Deficiency:
- **Concentration**: 0.1 mg/ml
- **Dose**: 0.1 mg three times daily
- **Duration**: 16 weeks with monitoring
- **Monitoring**: IGF-1 levels, growth velocity

### Cardiovascular Disease:
- **Concentration**: 0.2 mg/ml
- **Dose**: 0.2 mg daily
- **Duration**: Long-term maintenance
- **Monitoring**: Cardiac function, blood pressure

### Age-Related GH Decline:
- **Concentration**: 0.1 mg/ml
- **Dose**: 0.05-0.1 mg twice daily
- **Duration**: 12-week cycles
- **Monitoring**: IGF-1, body composition

### Muscle Wasting Conditions:
- **Concentration**: 0.2 mg/ml
- **Dose**: 0.2 mg daily
- **Duration**: 12-24 weeks
- **Monitoring**: Muscle mass, strength assessments

## Administration Guidelines

### Injection Technique:
1. Use 27-30 gauge, 0.5-1 inch needle
2. Clean injection site with alcohol
3. Inject into subcutaneous tissue of abdomen, thigh, or deltoid
4. Rotate injection sites to prevent lipodystrophy
5. Inject slowly over 10-15 seconds

### Timing Considerations:
- **Optimal**: Empty stomach (2-3 hours post-meal)
- **Multiple Daily Doses**: Space 4-6 hours apart
- **Evening Dose**: 2-3 hours before bedtime
- **Consistency**: Same times daily for optimal pulsatile GH release

### Cycling Protocol:
- **Standard Cycle**: 12-16 weeks on, 4 weeks off
- **Long-term Use**: Monitor for desensitization
- **Break Periods**: Allow GH axis recovery
- **Re-introduction**: May require dose adjustment

## Safety Parameters

### Baseline Testing:
- IGF-1 and IGFBP-3 levels
- Growth hormone stimulation test
- Comprehensive metabolic panel
- Cardiovascular assessment
- Bone density (if indicated)

### Monitoring During Treatment:
- IGF-1 levels every 4 weeks
- Growth hormone response testing
- Blood pressure monitoring
- Blood glucose monitoring
- Cortisol and prolactin levels

### Contraindications:
- Active malignancy
- Severe heart failure
- Uncontrolled diabetes
- Known hypersensitivity to hexarelin
- Pregnancy/lactation

### Adverse Effects:
- Generally well-tolerated
- Transient injection site reactions
- Potential water retention
- Possible increased appetite
- Risk of hypercortisolism at high doses
- Potential hyperprolactinemia

## Special Considerations

### Desensitization Risk:
- May occur with chronic high-dose use
- Monitor GH response regularly
- Consider dose holidays
- Adjust dosing based on IGF-1 levels

### Age-Related Dosing:
- **Adults**: Standard dosing protocols
- **Elderly**: May require dose adjustment
- **Children**: Limited data, use with extreme caution

### Drug Interactions:
- Monitor with corticosteroids (may reduce efficacy)
- Consider interactions with insulin
- May affect cortisol production
- Coordinate with other hormone therapies

### Cardiovascular Considerations:
- May improve cardiac function
- Monitor blood pressure
- Beneficial effects in heart failure
- Consider in post-cardiac event recovery

## Clinical Endpoints

### Treatment Success Indicators:
- Increased IGF-1 levels (target: age-appropriate range)
- Improved body composition (increased lean mass)
- Enhanced cardiac function parameters
- Improved exercise capacity
- Better metabolic markers

### Growth Hormone Response:
- **Acute Response**: 7-15 fold increase in GH
- **Peak Time**: 15-30 minutes post-injection
- **Duration**: Return to baseline by 2 hours
- **Tolerance**: Monitor for decreased response

### Duration Guidelines:
- **Initial Effects**: 2-4 weeks for IGF-1 increase
- **Body Composition**: 8-12 weeks for significant changes
- **Metabolic Benefits**: 12-16 weeks for full effects
- **Maintenance**: Ongoing with periodic assessment

### Combination Therapy:
- May be combined with GHRH for synergistic effects
- Consider with other peptides for enhanced benefits
- Coordinate with comprehensive hormone optimization
- Monitor for additive effects on GH axis